title: Surgical Outcomes for Persistent Macular Hole After Ocriplasmin.
abstract: OBJECTIVE
  To report surgical and visual acuity outcomes in eyes with unresolved full-thickness macular hole (FTMH) after treatment with ocriplasmin who subsequently underwent vitrectomy.
  
  
  METHODS
  Retrospective case series of four eyes. Vision and anatomy via optical coherence tomography (OCT) were assessed before and after intravitreal ocriplasmin as well as 6 months after subsequent vitrectomy.
  
  
  RESULTS
  Initial visual acuity ranged from 20/70 to 20/200. OCT showed focal vitreomacular traction (VMT) with FTMH ranging from 136 to 311 µm in diameter. Following ocriplasmin, VMT released in all four eyes without closure of the FTMH. All FTMHs enlarged over follow-up after ocriplasmin (mean increase 133 µm). Subsequent vitrectomy led to anatomic FTMH closure in all eyes. Final vision improved in all eyes (20/30 to 20/70).
  
  
  CONCLUSIONS
  Initial ocriplasmin treatment of FTMH in this series of patients did not reduce the effectiveness of vitrectomy, which was required for definitive FTMH repair.
authors.forename: Gregory D
authors.initials: GD
authors.lastname: Lee
authors.forename: Lauren S
authors.initials: LS
authors.lastname: Taney
authors.forename: Adam H
authors.initials: AH
authors.lastname: Rogers
authors.forename: Chirag P
authors.initials: CP
authors.lastname: Shah
authors.forename: Jay S
authors.initials: JS
authors.lastname: Duker
authors.forename: Caroline R
authors.initials: CR
authors.lastname: Baumal
mesh_terms: D000368:Aged; D005260:Female; D005341:Fibrinolysin / Q000627:therapeutic use*; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010446:Peptide Fragments / Q000627:therapeutic use*; D012167:Retinal Perforations / Q000175:diagnosis / Q000188:drug therapy / Q000503:physiopathology / Q000601:surgery*; D012189:Retrospective Studies; D041623:Tomography, Optical Coherence; D017211:Treatment Failure; D016896:Treatment Outcome; D014792:Visual Acuity / Q000502:physiology; D014821:Vitrectomy
chemical_list: D005343:Fibrinolytic Agents; D010446:Peptide Fragments; C054561:microplasmin; D005341:Fibrinolysin